Novo Nordisk A/S’s sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly & Co. in ...

Eli Lilly and Company is gearing up for its second quarter earnings report this Thursday, before the market opens. The pharmaceutical giant has witnessed significant revenue boosts from its ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

A new drug that skips neurons and targets support cells cut weight and improved insulin response in lab animals, without ...

Eli Lilly's stock is lagging the S&P 500 since April, potentially allowing a catch-up trade if results impress. Medicare may ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

Dr. Tim Church predicted recently that GLP-1 agonists, GLP-1 /GIP agonists and similar prescription drugs will soon be as ...

In July, spending on TV ads for prescription drugs reached a low not seen since this time last year. | In July, spending on TV ads for prescription drugs reached a low not seen since this time last ...

President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...

I have been diagnosed with mild sleep apnea. (No surprise there as symptoms were omnipresent.) CPAP machines seem incredibly uncomfortable. Are they the preferred gold standard even for mild sleep ...